CN Patent

CN1934091B — 治疗神经变性障碍的咪唑化合物

Assigned to Pfizer Products Inc · Expires 2012-02-08 · 14y expired

What this patent protects

本发明涉及式I化合物其中R 1 、R 2 、R 3 、R 4 、R 6 、R 7 和A是如本文所定义的。式I化合物具有抑制Aβ-肽产生的活性。本发明也涉及包含式I化合物的、治疗哺乳动物疾病和障碍的药物组合物和方法，例如神经变性和/或神经病学障碍，例如阿尔茨海默氏病。

USPTO Abstract

本发明涉及式I化合物其中R 1 、R 2 、R 3 、R 4 、R 6 、R 7 和A是如本文所定义的。式I化合物具有抑制Aβ-肽产生的活性。本发明也涉及包含式I化合物的、治疗哺乳动物疾病和障碍的药物组合物和方法，例如神经变性和/或神经病学障碍，例如阿尔茨海默氏病。

Drugs covered by this patent

nirogacestat-hydrobromide (NIROGACESTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN1934091B
Jurisdiction: CN
Classification: —
Expires: 2012-02-08
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Products Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.